PF07104091
CAS No. 2460249-19-6
PF07104091( PF-07104091 )
Catalog No. M28851 CAS No. 2460249-19-6
PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 915 | In Stock |
|
| 2MG | 519 | In Stock |
|
| 5MG | 824 | In Stock |
|
| 10MG | 1207 | In Stock |
|
| 25MG | 1796 | In Stock |
|
| 50MG | 2372 | In Stock |
|
| 100MG | 3190 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePF07104091
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
-
DescriptionPF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
-
In Vitro——
-
In Vivo——
-
SynonymsPF-07104091
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2460249-19-6
-
Formula Weight404.46
-
Molecular FormulaC19H28N6O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1=CC(COC)=NN1C)C2=CC(=NN2)[C@@H]3C[C@H](OC(NC(C)C)=O)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yamaguchi T, et al. Determination of 7-chloro-3-(4-methyl-1-piperazinyl)-4h-1,2,4-benzothiadiazine-1,1-dioxide (DU-717) in plasma using electron-capture gas chromatography. J Chromatogr. 1978 Oct 11;160(1):181-90.
molnova catalog
related products
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.
-
CDK5 inhibitor 20-22...
CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.
-
Dalpiciclib
Dalpiciclib is a highly selective, orally bioavailable, and comparable potency inhibitor of CDK4 and CKD6 with IC50s of 12.4?nM and 9.9?nM, respectively.
Cart
sales@molnova.com